Antibacterial drug discovery and structure-based design

Drug Discovery Today

Volumn 11, Issue 9-10, 2006, Pages 391-404

  Barker, John J ^a  

^a EVOTEC UK LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; AMINE OXIDASE (FLAVIN CONTAINING); AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFOXITIN; CEPHALOSPORIN; CHLORAMPHENICOL DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; FOSMIDOMYCIN; INDOLMYCIN; ISONIAZID; LINEZOLID; MACROLIDE; MULTIDRUG RESISTANCE PROTEIN; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL) HEXANOYL]PROLINAMIDE; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; N [1 TERT BUTYL 2 OXO 2 [4 (2 THIAZOLYLMETHYL) 1 PIPERAZINYL]ETHYL] 3 CYCLOPENTYL 2 (N FORMYL N HYDROXYAMINOMETHYL)PROPIONAMIDE; OXAZOLIDINONE DERIVATIVE; OXAZOLIDINONE LINEZOLID; PAROMOMYCIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFALAZIL; RIFAMPICIN DERIVATIVE; STREPTOGRAMIN DERIVATIVE; TAK 083; TRIAZOLE DERIVATIVE; TRICLOSAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACILLUS ANTHRACIS; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BIOSYNTHESIS; CELL DIVISION; CELL WALL; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DEGRADATION; DRUG DESIGN; DRUG HYDROLYSIS; DRUG INDUSTRY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HOSPITAL; HUMAN; NONHUMAN; PROTEIN PROTEIN INTERACTION; REVIEW; RNA TRANSLATION; STRUCTURAL GENOMICS; UNSPECIFIED SIDE EFFECT;

ACETAMIDES; AMINO ACYL-TRNA SYNTHETASES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; CRYSTALLOGRAPHY, X-RAY; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, BACTERIAL; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MONOAMINE OXIDASE INHIBITORS; OXAZOLIDINONES; PROTEIN BIOSYNTHESIS; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE II INHIBITORS; TRANSCRIPTION, GENETIC;

EID: 33646112903     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.03.001     Document Type: Review

References (144)

1. Projan S.J., and Shlaes D.M. Antibacterial drug discovery: is it all downhill from here?. Clin. Microbiol. Infect. 10 (2004) 18-22
2. Bush K. Antibacterial drug discovery in the 21st century. Clin. Microbiol. Infect. 10 (2004) 10-17
3. Zetola N., et al. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect. Dis. 5 (2005) 275-286
4. Boggs A.F., and Miller G.H. Antibacterial drug discovery: is small pharma the solution?. Clin. Microbiol. Infect. 10 (2004) 32-36
5. Schmid M.B. Seeing is believing: the impact of structural genomics on antimicrobial drug discovery. Nat. Rev. Microbiol. 2 (2004) 739-746
6. Kantardjieff K., and Rupp B. Structural bioinformatic approaches to the discovery of new antimycobacterial drugs. Curr. Pharm. Des. 10 (2004) 3195-3211
7. Chan P.F., et al. Finding the gems using genomic discovery: antibacterial drug discovery strategies - the successes and the challenges. Drug Discov. Today: Ther. Strat. 1 (2004) 519-527
8. Garcia-Lara J., et al. Staphylococcus aureus: the search for novel targets. Drug Discov. Today 10 (2005) 643-651
9. Congreve M., et al. Structural biology and drug discovery. Drug Discov. Today 10 (2005) 895-907
10. Hermann T. Drugs targeting the ribosome. Curr. Opin. Struct. Biol. 15 (2005) 355-366
11. DePristo M.A., et al. Heterogeneity and inaccuracy in protein structures solved by X-ray crystallography. Structure 12 (2004) 831-838
12. Wishart D. NMR spectroscopy and protein structure determination: applications to drug discovery and development. Curr. Pharm. Biotechnol. 6 (2005) 105-120
13. Kopp J., and Schwede T. Automated protein structure homology modeling: a progress report. Pharmacogenomics 5 (2004) 405-416
14. Takeda-Shitaka M., et al. Protein structure prediction in structure based drug design. Curr. Med. Chem. 11 (2004) 551-558
15. Anderson A.C. The process of structure-based drug design. Chem. Biol. 10 (2003) 787-797
16. Gill A., et al. The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography. ChemBioChem 6 (2005) 506-512
17. Carr R.A., et al. Fragment-based lead discovery: leads by design. Drug Discov. Today 10 (2005) 987-992
18. Verdonk M.L., and Hartshorn M.J. Structure-guided fragment screening for lead discovery. Curr. Opin. Drug Discov. Devel. 7 (2004) 404-410
19. Erlanson D.A., and Hansen S.K. Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly. Curr. Opin. Chem. Biol. 8 (2004) 399-406
20. Villar H.O., et al. Using NMR for ligand discovery and optimization. Curr. Opin. Chem. Biol. 8 (2004) 387-391
21. Anderson A.C., and Wright D.L. The design and docking of virtual compound libraries to structures of drug targets. Curr. Comp. Aided Drug Des. 1 (2005) 103-127
22. Shoichet B.K. Virtual screening of chemical libraries. Nature 432 (2004) 862-865
23. Chin D.N., et al. Integration of virtual screening into the drug discovery process. Mini Rev. Med. Chem. 4 (2004) 1053-1065
24. Kitchen D.B., et al. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discov. 3 (2004) 935-949
25. Barril X. Virtual screening in structure-based drug discovery. Mini Rev. Med. Chem. 4 (2004) 779-791
26. Schneider G., and Fechner U. Computer-based de novo design of drug-like molecules. Nat. Rev. Drug Discov. 4 (2005) 649-663
27. Douguet D., et al. LEA3D: a computer-aided ligand design for structure-based drug design. J. Med. Chem. 48 (2005) 2457-2468
28. Raha K., and Merz Jr. K.M. Large-scale validation of a quantum mechanics based scoring function: predicting the binding affinity and the binding mode of a diverse set of protein-ligand complexes. J. Med. Chem. 48 (2005) 4558-4575
29. Kuhn B., et al. Validation and use of the MM-PBSA approach for drug discovery. J. Med. Chem. 48 (2005) 4040-4048
30. Stevens D.L., et al. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev. Anti. Infect. Ther. 2 (2004) 51-59
31. Reck F., et al. Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J. Med. Chem. 48 (2005) 499-506
32. Hu Y., et al. Identification of selective inhibitors for the glycosyltransferase MurG via high-throughput screening. Chem. Biol. 11 (2004) 703-711
33. Smith R.M., and Wu G.Y. Structure-based design of hepatitis C virus inhibitors. J. Viral Hepat. 10 (2003) 405-412
34. Wlodawer A. Structure-based design of AIDS drugs and the development of resistance. Vox Sang. 83 (2002) 23-26
35. Marrero-Ponce Y., et al. Atom, atom-type, and total nonstochastic and stochastic quadratic fingerprints: a promising approach for modeling of antibacterial activity. Bioorg. Med. Chem. 13 (2005) 2881-2899
36. Vidal S., et al. Beta-lactam screening by specific residues of the OmpF eyelet. J. Med. Chem. 48 (2005) 1395-1400
37. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70 (2001) 369-413
38. Espeli O., and Marians K.J. Untangling intracellular DNA topology. Mol. Microbiol. 52 (2004) 925-931
39. Mitscher L.A. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem. Rev. 105 (2005) 559-592
40. Costenaro L., et al. Small-angle X-ray scattering reveals the solution structure of the full-length DNA gyrase a subunit. Structure 13 (2005) 287-296
41. Tanitame A., et al. Synthesis and antibacterial activity of novel and potent DNA gyrase inhibitors with azole ring. Bioorg. Med. Chem. 12 (2004) 5515-5524
42. Tanitame A., et al. Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives. J. Med. Chem. 47 (2004) 3693-3696
43. Tanitame A., et al. Design, synthesis and structure-activity relationship studies of novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity. Bioorg. Med. Chem. Lett. 14 (2004) 2857-2862
44. Tanitame A., et al. Potent DNA gyrase inhibitors; novel 5-vinylpyrazole analogues with Gram-positive antibacterial activity. Bioorg. Med. Chem. Lett. 14 (2004) 2863-2866
45. Boehm H.J., et al. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimisation. A promising alternative to random screening. J. Med. Chem. 43 (2000) 2664-2674
46. Schechner M., et al. Functionality maps of the ATP binding site of DNA gyrase B: generation of a consensus model of ligand binding. J. Med. Chem. 47 (2004) 4373-4390
47. Bellon S., et al. Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase. Antimicrob. Agents Chemother. 48 (2004) 1856-1864
48. Mooney R.A., and Landick R. RNA polymerase unveiled. Cell 98 (1999) 687-690
49. Vassylyev D.G., et al. Crystal structure of a bacterial RNA polymerase holoenzyme at 2.6 Å resolution. Nature 417 (2002) 712-719
50. Zhang G., et al. Crystal structure of Thermus aquaticus core RNA polymerase at 3.3 Å resolution. Cell 98 (1999) 811-824
51. Murakami K.S., et al. Structural basis of transcription initiation: RNA polymerase holoenzyme at 4 Å resolution. Science 296 (2002) 1280-1284
52. Murakami K.S., et al. Structural basis of transcription initiation: an RNA polymerase holoenzyme-DNA complex. Science 296 (2002) 1285-1290
53. MacDougall I.J., et al. Homology modelling of RNA polymerase and associated transcription factors from Bacillus subtilis. J. Mol. Graph. Model. 23 (2005) 297-303
54. Suchland R.J., et al. Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil. Antimicrob. Agents Chemother. 49 (2005) 1120-1126
55. Mukhtar T.A., and Wright G.D. Streptogramins, oxazolidinones, and other inhibitors of bacterial protein synthesis. Chem. Rev. 105 (2005) 529-542
56. Foloppe N., et al. A structure-based strategy to identify new molecular scaffolds targeting the bacterial ribosomal A-site. Bioorg. Med. Chem. 12 (2004) 935-947
57. Carter A.P. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 407 (2000) 340-348
58. Pohlmann J., and Brotz-Oesterhelt H. New aminoacyl-tRNA synthetase inhibitors as antibacterial agents. Curr. Drug Targets Infect. Disord. 4 (2004) 261-272
59. Kanamaru T., et al. In vitro and In vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection. Antimicrob. Agents Chemother. 45 (2001) 2455-2459
60. Kitabatake M., et al. Indolmycin resistance of Streptomyces coelicolor A3(2) by induced expression of one of its two tryptophanyl-tRNA synthetases. J. Biol. Chem. 277 (2002) 23882-23887
61. Buddha M.R., and Crane B.R. Structure and activity of an aminoacyl-tRNA synthetase that charges tRNA with nitro-tryptophan. Nat. Struct. Mol. Biol. 12 (2005) 274-275
62. Clements J.M., et al. Peptide deformylase inhibitors, potential for a new class of broad spectrum antibacterials. Curr. Med. Chem. Anti-Infect. Agents 1 (2002) 239-249
63. Johnson K.W., et al. PDF inhibitors: an emerging class of antibacterial drugs. Curr. Drug Targets Infect. Disord. 5 (2005) 39-52
64. Jain R., et al. Bacterial Peptide deformylase inhibitors: a new class of antibacterial agents. Curr. Med. Chem. 12 (2005) 1607-1621
65. Rajagopalan P.T., and Pei D. Oxygen-mediated inactivation of peptide deformylase. J. Biol. Chem. 273 (1998) 22305-22310
66. Molteni V., et al. Identification of novel potent bicyclic peptide deformylase inhibitors. Bioorg. Med. Chem. Lett. 14 (2004) 1477-1481
67. Cali P., et al. Isoxazole-3-hydroxamic acid derivatives as peptide deformylase inhibitors and potential antibacterial agents. Bioorg. Med. Chem. Lett. 14 (2004) 5997-6000
68. Howard M.H., et al. A novel class of inhibitors of peptide deformylase discovered through high-throughput screening and virtual ligand screening. J. Med. Chem. 47 (2004) 6669-6672
69. El Zoeiby A., et al. Structure and function of the Mur enzymes: development of novel inhibitors. Mol. Microbiol. 47 (2003) 1-12
70. Francisco G.D., et al. Phenyl thiazolyl urea and carbamate derivatives as new inhibitors of bacterial cell-wall biosynthesis. Bioorg. Med. Chem. Lett. 14 (2004) 235-238
71. Jennings A., and Tennant M. Discovery strategies in a BioPharmaceutical startup: maximising your chances of success using computational filters. Curr. Pharm. Des. 11 (2005) 335-344
72. Macheboeuf P., et al. Active site restructuring regulates ligand recognition in class A penicillin-binding proteins. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 577-582
73. Gherman B.F., et al. Mixed quantum mechanical/molecular mechanical (QM/MM) study of the deacylation reaction in a penicillin binding protein (PBP) versus in a class C beta-lactamase. J. Am. Chem. Soc. 126 (2004) 7652-7664
74. Then R.L. Antimicrobial dihydrofolate reductase inhibitors-achievements and future options: review. J. Chemother. 16 (2004) 3-12
75. Wyss P.C., et al. Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening. J. Med. Chem. 46 (2003) 2304-2312
76. Tedder M.E., et al. Structure-based design, synthesis, and antimicrobial activity of purine derived SAH/MTA nucleosidase inhibitors. Bioorg. Med. Chem. Lett. 14 (2004) 3165-3168
77. Heath R.J., and Rock C.O. Fatty acid biosynthesis as a target for novel antibacterials. Curr. Opin. Investig. Drugs 5 (2004) 146-153
78. Heath R.J., et al. Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. Appl. Microbiol. Biotechnol. 58 (2002) 695-703
79. Nie Z., et al. Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents. J. Med. Chem. 48 (2005) 1596-1609
80. Pasqualoto K.F., et al. Rational design of new antituberculosis agents: receptor-independent four-dimensional quantitative structure-activity relationship analysis of a set of isoniazid derivatives. J. Med. Chem. 47 (2004) 3755-3764
81. Sivaraman S., et al. Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. J. Med. Chem. 47 (2004) 509-518
82. Ballew N.L. Affinium Pharmaceuticals Inc.: structure-guided drug discovery. Chem. Biol. 11 (2004) 583-584
83. Proteau P.J. 1-Deoxy-D-xylulose 5-phosphate reductoisomerase: an overview. Bioorg. Chem. 32 (2004) 483-493
84. Mac Sweeney A., et al. The crystal structure of E. coli 1-deoxy-D-xylulose-5-phosphate reductoisomerase in a ternary complex with the antimalarial compound fosmidomycin and NADPH reveals a tight-binding closed enzyme conformation. J. Mol. Biol. 345 (2005) 115-127
85. Cheng F., and Oldfield E. Inhibition of isoprene biosynthesis pathway enzymes by phosphonates, bisphosphonates, and diphosphates. J. Med. Chem. 47 (2004) 5149-5158
86. Oliva M.A., et al. Structural insights into FtsZ protofilament formation. Nat. Struct. Mol. Biol. 11 (2004) 1243-1250
87. Sutherland A.G., et al. Structure-based design of carboxybiphenylindole inhibitors of the ZipA-FtsZ interaction. Org. Biomol. Chem. 1 (2003) 4138-4140
88. Jennings L.D., et al. Design and synthesis of indolo[2,3-a]quinolizin-7-one inhibitors of the ZipA-FtsZ interaction. Bioorg. Med. Chem. Lett. 14 (2004) 1427-1431
89. Jennings L.D., et al. Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interaction. Bioorg. Med. Chem. 12 (2004) 5115-5131
90. Rush III T.S., et al. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J. Med. Chem. 48 (2005) 1489-1495
91. Marra A. Can virulence factors be viable antibacterial targets?. Expert. Rev. Anti. Infect. Ther. 2 (2004) 61-72
92. Ascenzi P., et al. Anthrax toxin: a tripartite lethal combination. FEBS Lett. 531 (2002) 384-388
93. Soelaiman S., et al. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J. Biol. Chem. 278 (2003) 25990-25997
94. Shen Y., et al. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 3242-3247
95. Drum C.L., et al. Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature 415 (2002) 396-402
96. Hoeflich K.P., and Ikura M. Calmodulin in action: diversity in target recognition and activation mechanisms. Cell 108 (2002) 739-742
97. Lee Y.S., et al. Discovery of a small molecule that inhibits the interaction of anthrax edema factor with its cellular activator, calmodulin. Chem. Biol. 11 (2004) 1139-1146
98. Hicks R.P., et al. The anthrax protective antigen (PA63) bound conformation of a peptide inhibitor of the binding of lethal factor to PA63: as determined by trNOESY NMR and molecular modeling. J. Med. Chem. 47 (2004) 5347-5355
99. Duesbery N.S., et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280 (1998) 734-737
100. Park J.M., et al. Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science 297 (2002) 2048-2051
101. Stubbs M.T. Anthrax X-rayed: new opportunities for biodefence. Trends Pharmacol. Sci. 23 (2002) 539-541
102. Forino M., et al. Efficient synthetic inhibitors of anthrax lethal factor. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9499-9504
103. Chambers H.F. Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. J. Infect. Dis. 179 (1999) S353-S359
104. Nikaido H. Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. Semin. Cell Dev. Biol. 12 (2001) 215-223
105. Thiolas A., et al. Resistance to imipenem, cefepime, and cefpirome associated with mutation in Omp36 osmoporin of Enterobacter aerogenes. Biochem. Biophys. Res. Commun. 317 (2004) 851-856
106. Li X.Z., and Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 64 (2004) 159-204
107. Helfand M.S., and Bonomo R.A. Beta-lactamases: a survey of protein diversity. Curr. Drug Targets Infect. Disord. 3 (2003) 9-23
108. Morlot C., et al. Crystal structure of a peptidoglycan synthesis regulatory factor (PBP3) from Streptococcus pneumoniae. J. Biol. Chem. 280 (2005) 15984-15991
109. Venkatesan A.M., et al. Structure-activity relationship of 6-methylidene penems bearing tricyclic heterocycles as broad-spectrum beta-lactamase inhibitors: crystallographic structures show unexpected binding of 1. 4-thiazepine intermediates. J. Med. Chem. 47 (2004) 6556-6568
110. Venkatesan A.M., et al. Novel imidazole substituted 6-methylidene-penems as broad-spectrum beta-lactamase inhibitors. Bioorg. Med. Chem. 12 (2004) 5807-5817
111. Diaz N., et al. Molecular dynamics simulations of the TEM-1 beta-lactamase complexed with cephalothin. J. Med. Chem. 48 (2005) 780-791
112. Tondi D., et al. Structure-based optimization of a non-beta-lactam lead results in inhibitors that do not up-regulate beta-lactamase expression in cell culture. J. Am. Chem. Soc. 127 (2005) 4632-4639
113. Wright G.D., et al. Aminoglycoside antibiotics. Structures, functions, and resistance. Adv. Exp. Med. Biol. 456 (1998) 27-69
114. The Aminoglycoside Resistance Study Groups. The most frequently occurring aminoglycoside resistance mechanisms-combined results of surveys in eight regions of the world. J. Chemother. 7 (1995) 17-30
115. Vetting M.W., et al. A bacterial acetyltransferase capable of regioselective N-acetylation of antibiotics and histones. Chem. Biol. 11 (2004) 565-573
116. Langton K.P., et al. Antiobiotic resitance: multidrug efflux proteins, a common transport mechanism? Nat. Prod. Rep. 22 (2005) 439-451
117. Kaatz G.W. Inhibition of bacterial efflux pumps: a new strategy to combat increasing antimicrobial agent resistance. Expert Opin. Emerg. Drugs 7 (2002) 223-233
118. Choi C.H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 5 (2005) 30-43
119. McKeegan K.S., et al. Structural understanding of efflux-mediated drug resistance: potential routes to efflux inhibition. Curr. Opin. Pharmacol. 4 (2004) 479-486
120. Putman M., et al. Molecular properties of bacterial multidrug transporters. Microbiol. Mol. Biol. Rev. 64 (2000) 672-693
121. McKeegan K.S., et al. The structure and function of drug pumps: an update. Trends Microbiol. 11 (2003) 21-29
122. Borges-Walmsley M.I., et al. Structure and function of efflux pumps that confer resistance to drugs. Biochem. J. 376 (2003) 313-338
123. Chang C., et al. In silico strategies for modeling membrane transporter function. Drug Discov. Today 10 (2005) 663-671
124. Chang G., and Roth C.B. Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science 293 (2001) 1793-1800
125. Chang G. Structure of MsbA from Vibrio cholera: a multidrug resistance ABC transporter homolog in a closed conformation. J. Mol. Biol. 330 (2003) 419-430
126. Chang G. Multidrug resistance ABC transporters. FEBS Lett. 555 (2003) 102-105
127. Locher K.P., et al. The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. Science 296 (2002) 1091-1098
128. Murakami S., et al. Crystal structure of bacterial multidrug efflux transporter AcrB. Nature 419 (2002) 587-593
129. Abramson J., et al. Structure and mechanism of the lactose permease of Escherichia coli. Science 301 (2003) 610-615
130. Huang Y., et al. Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 301 (2003) 616-620
131. Ma C., and Chang G. Structure of the multidrug resistance efflux transporter EmrE from Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 2852-2857
132. Ahmed M., et al. A protein that activates expression of a multidrug efflux transporter upon binding the transporter substrates. J. Biol. Chem. 269 (1994) 28506-28513
133. Zheleznova E.E., et al. Structural basis of multidrug recognition by BmrR, a transcription activator of a multidrug transporter. Cell 96 (1999) 353-362
134. Vazquez-Laslop N., et al. Recognition of multiple drugs by a single protein: a trivial solution of an old paradox. Biochem. Soc. Trans. 28 (2000) 517-520
135. Higgins M.K., et al. Structure of the ligand-blocked periplasmic entrance of the bacterial multidrug efflux protein TolC. J. Mol. Biol. 342 (2004) 697-702
136. Higgins M.K., et al. Structure of the periplasmic component of a bacterial drug efflux pump. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9994-9999
137. Payne R.J., et al. Design and synthesis of aromatic inhibitors of anthranilate synthase. Org. Biomol. Chem. 3 (2005) 2271-2281
138. Sem D.S., et al. Systems-based design of bi-ligand inhibitors of oxidoreductases: filling the chemical proteomic toolbox. Chem. Biol. 11 (2004) 185-194
139. Frenois F., et al. Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis. Mol. Cell 16 (2004) 301-307
140. Khedkar S.A., et al. Comparative protein modeling of methionine S-adenosyltransferase (MAT) enzyme from Mycobacterium tuberculosis: a potential target for antituberculosis drug discovery. J. Mol. Graph. Model. 23 (2005) 355-366
141. Vanheusden V., et al. Discovery of bicyclic thymidine analogues as selective and high-affinity inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase. J. Med. Chem. 47 (2004) 6187-6194
142. Ferrari S., et al. Inhibitor specificity via protein dynamics: insights from the design of antibacterial agents targeted against thymidylate synthase. Chem. Biol. 10 (2003) 1183-1193
143. Tondi D., et al. Improving specificity vs bacterial thymidylate synthases through N-dansyl modulation of didansyltyrosine. J. Med. Chem. 48 (2005) 913-916
144. Whittington D.A., et al. Crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8146-8150